PRODUCT LITERATURE

Roflumilast: In Chronic Obstructive Pulmonary Disease

---

Roflumilast is an orally administered, selective phosphodiesterase 4 inhibitor that is a novel treatment for patients with severe chronic obstructive pulmonary disease (COPD). Across four randomized, double-blind, multinational trials in patients with moderate to severe or severe COPD, roflumilast 500 microg/day produced significantly greater improvements from baseline than placebo in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV(1))

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Forespi

Specific Detail Info

Drugs. 2010 Aug 20;70(12):1615-27.

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment